Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation

Journal of Clinical Oncology

Volumn 17, Issue 11, 1999, Pages 3531-3539

  Leyvraz, Serge ^a   Perey, L ^a   Rosti, G ^a   Lange, A ^a   Pampallona, S ^a   Peters, R ^a   Humblet, Y ^a   Bosquee L ^a   Pasini, F ^a   Marangolo, M ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VOMITING;

EID: 0032703763     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.11.3531     Document Type: Article

References (50)

1. Hyde L, Yee J, Wilson R, et al: Cell type and the natural history of lung cancer. JAMA 193:140-142, 1965
2. Muggia FM, Krezoski SK, Hansen HH: Cell kinetic studies in patients with small cell carcinoma of the lung. Cancer 34:1683-1690, 1974
3. Weiss W, Boucot KR, Cooper DA: The histopathology of bronchogenic carcinoma and its relation to growth rate, metastasis and prognosis. Cancer 26:966-970, 1970
4. Green RA, Humphrey E, Close H, et al: Alkylating agents in bronchogenic carcinoma. Am J Med 46:516-525, 1969
5. Weiss RB: Small-cell carcinoma of the lung: Therapeutic management. Ann Int Med 88:522-531, 1978
6. Lowenbraun S, Bartolucci A, Smalley RV, et al: The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer 44:406-413, 1979
7. Aisner J, Alberto P, Bitran J, et al: Role of chemotherapy in small cell lung cancer: A consensus report of the International Association for the Study of Lung Cancer Workshop. Cancer Treat Rep 67:37-43, 1983
8. Cohen MH, Creaven PJ, Fossieck BE, et al: Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 61:349-354, 1977
9. Holoye PY, Kalbfleisch J: The influence of myelosuppression on the response to chemotherapy in small cell bronchogenic carcinoma. Cancer 54:411-415, 1984
10. Livingstone RB, Moore TN, Heilbran L, et al: Small-cell carcinoma of the lung: Combined chemotherapy and radiation - A South-West Oncology Group study. Ann Intern Med 88:194-199, 1978
11. Sierocki JS, Hilaris BS, Hopfan S, et al: cis-dichlorodiammineplatinum (II) and VP-16-213: An active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 63:1593-1597, 1979
12. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992
13. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861, 1991
14. Evans WK, Feld R, Murray N, et al: Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Int Med 107:451-458, 1987
15. Ettinger DS, Karp JE, Abeloff MD, et al: Intermittent high-dose cyclophosphamide chemotherapy for small cell carcinoma of the lung. Cancer Treat Rep 62:413-424, 1978
16. Klasa RJ, Murray N, Coldman AJ: Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 9:499-508, 1991
17. Figueredo AT, Hryniuk WM, Strautmanis I, et al. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 3:54-64, 1985
18. Johnson DH, Einhorn LH, Birch R, et al: A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 5:1731-1738, 1987
19. Ihde DC, Mulshine JL, Kramer BS, et al: Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 12:2022-2034, 1994
20. Arriagada R, Le Chevalier T, Pignon JP, et al: Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 329:1848-1852, 1993
21. Woll PJ, Hodgetts J, Lomax L, et al: Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 13:652-659, 1995
22. Steward WP, von Pawel J, Gatzemeier U, et al: Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 300 patients. J Clin Oncol 16:642-650, 1998
23. Thatcher N, Sambrook R, Stephens RJ, et al: Dose intensification (DI) with G-CSF improves survival in small cell lung cancer (SCLC): Results of a randomized trial. Proc Am Soc Clin Oncol 17:456a, 1998 (abstr 1754)
24. Elias AD, Cohen BF: Dose-intensive therapy in lung cancer, in Armitage JO, Antman KH (eds): High-Dose Cancer Therapy: Pharmacology, Hematopoietins. Stem cells (ed 2). Baltimore. MD, Williams and Wilkins, 1995, pp 824-846
25. Elias AD, Ibrahim J, Skavin AT, et al: Dose-intensive therapy for limited-stage small-cell lung cancer: Long-term outcome. J Clin Oncol 17:1175-1184, 1999
26. Humblet Y, Symann M, Bosly A, et al: Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: A randomized study. J Clin Oncol 5:1864-1873, 1987
27. Souhami RL, Finn G, Gregory WM, et al: High-dose cyclophosphamide in small-cell carcinoma of the lung. J Clin Oncol 3:958-963, 1985
28. Farha P, Spitzer G, Valdivieso M: High-dose chemotherapy and autologous bone marrow transplantation for the treatment of small cell lung carcinoma. Cancer 52:1351-1355, 1983
29. Pettengell R, Woll PJ, Thatcher N, et al: Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 13:148-156, 1995
30. Leyvraz S, Ketterer N, Perey L, et al: Intensification of chemotherapy for the treatment of solid tumours: Feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor. Br J Cancer 72:178-182, 1995
31. Marmont A, Tyndall A, Gratwohl A, et al: Haemopoietic precursor-cell transplants for autoimmune diseases. Lancet 345:978, 1995
32. World Health Organization: WHO Handbook for Reporting the Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, offset publication 48, 1979
33. Castellanos AM, Fields WS: Grading of neurotoxicity in cancer therapy. J Clin Oncol 4:1277-1278, 1986
34. R Simon: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
35. Armitage P, Berry D: Statistical methods in medical research (ed 2). Oxford, England, Blackwell Scientific, 1987
36. Kaplan EL, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 53:457-481, 1958
37. Greenwood M: Reports on public health and medical subjects: The natural duration of cancer. HMSO 33:1-16, 1926
38. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Brit J Cancer 35:1-39, 1977
39. Longo DL, Duffey PL, DeVita VT Jr, et al: The calculation of actual or received dose intensity: A comparison of published methods. J Clin Oncol 9:2042-2051, 1991
40. Janssen-Heijnen MLG, Schipper RM, Klinkhamer PJJM, et al: Improvement and plateau in survival of small-cell lung cancer since 1975: A population-based study. Ann Oncol 9:543-547, 1998
41. Lassen U, Østerlind K, Hansen M, et al: Long-term survival in small-cell lung cancer: Posttreatment characteristics in patients surviving 5 to 18+ years - An analysis of 1714 consecutive patients. J Clin Oncol 13:1215-1220, 1995
42. Souhami RL, Law K: Longevity in small cell lung cancer: A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer 61:584-589, 1990
43. Humblet Y, Feyens A-M, Sekhavat M, et al: Immunological and pharmacological removal of small cell lung cancer from bone marrow autografts. Cancer Res 49:5058-5061, 1989
44. Leyvraz S, Ketterer N, Vuichard P, et al: Sequential high-dose combination chemotherapy with granulocyte colony-stimulating factor and peripheral blood progenitor cells in patients with solid tumors: Intensification limited by nonhematologic toxic effects. J Natl Cancer Inst 85:1962-1964, 1993
45. Ayash LJ, Elias A, Wheeler C, et al: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitorcell support for metastatic breast cancer: A feasibility study. J Clin Oncol 12:37-44, 1994
46. Shapiro CL, Ayash L, Webb IJ, et al: Repetitive cycles of cyclophosphamide, thiotepa and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol 15:674-683, 1997
47. Rodenhuis S, Westermann A, Holtkamp MJ, et al: Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 14:1473-1483, 1996
48. Elias AD, Ayash LJ, Wheeler C, et al: Phase I study of high-dose ifosfamide, carboplatin, and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 15:373-379, 1995
49. Shea TC, Mason JR, Breslin M, et al: Reinfusion and serial measurements of carboplatin-mobilized peripheral blood progenitor cells in patients receiving multiple cycles of high-dose chemotherapy. J Clin Oncol 12:1012-1020, 1994
50. Hirsch FR, Osterlind K, Jensen LI, et al: The impact of abdominal computerized tomography on the pretreatment staging and prognosis of small cell lung cancer. Ann Oncol 3:469-474, 1992